ArticleCancer medicine2025
Extracellular Volume Fraction Combined With Pathological Features of α-SMA and FAP for Predicting the Prognosis of Patients With Pancreatic Ductal Adenocarcinoma After Surgery and Evaluating the Efficacy of Chemotherapy.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesThis study aimed to evaluate the extracellular matrix of pancreatic ductal adenocarcinoma (PDAC) using the extracellular volume fraction (fECV) derived from enhanced CT images, integrating fECV with α-SMA-positive cancer-associated fibroblasts (CAFs) and FAP-positive CAFs to investigate their relationship with clinicopathological characteristics and prognosis of patients with PDAC.
methodsA retrospective analysis of 124 patients who underwent surgical resection for PDAC was conducted. Immunohistochemistry was applied to determine the expression of α-SMA and FAP. fECV was calculated by attenuation values of PDAC and aorta. The Kaplan-Meier method was used to plot the postoperative overall survival (OS) and disease-free survival (DFS) curves. A Cox proportional hazards regression model was used to develop a predictive model.
resultsHigh α-SMA (OS: p < 0.001; DFS: p = 0.065) and FAP (OS: p < 0.001; DFS: p < 0.001) expressions and low fECV (OS: p < 0.001; DFS: p < 0.001) predict poor prognosis. Patients with co-high expression of α-SMA and FAP had worse OS and DFS. Multivariable analysis identified α-SMA (OS: hazard ratio [HR], 2.34 [95% CI, 1.30-4.21], p = 0.005), FAP (OS: HR, 4.43 [95% CI, 2.72-7.19], p < 0.001), and fECV (OS: HR, 0.58 [95% CI, 0.37-0.90], p = 0.015) as independent predictors of prognosis. The predictive model established by combining fECV with α-SMA and FAP in this study cohort demonstrated the best predictive value.
conclusionsThe integration of fECV with α-SMA and FAP expressions offers a robust method for predicting clinical outcomes in PDAC patients, potentially guiding treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.